Elevance Health: CEO Buys As CareBridge Drives Strong Growth

Elevance Health (ELV) is rated a contrarian 'Buy' despite recent significant headwinds, including a 20% stock drop following lowered 2Q25 EPS guidance due to rising medical costs and industry-wide morbidity. The bullish case highlights strong growth in its Carelon Services segment, particularly from the CareBridge acquisition, which is increasingly contributing to earnings, alongside an attractive valuation post-sell-off and CEO insider buying. Long-term tailwinds like a projected 6-7% industry CAGR driven by an aging population and strategic expansion into new markets like Texas and Florida are expected to mitigate ongoing challenges from cost inflation and potential regulatory shifts, such as the 'One Big Beautiful Bill Act'.

Analysis

Elevance Health (ELV) is facing significant operational and market pressure, evidenced by a 20% stock price decline following a downward revision of its 2025 EPS guidance to approximately $30, which implies a 0.1% year-over-year decrease. This revision stems from deteriorating fundamentals, including a rise in operating expenses (up 12% TTM) that outpaced revenue growth (up 10.2% TTM) and a higher-than-expected medical loss ratio of 88.9%, driven by increased morbidity and cost trends in its ACA and Medicaid businesses. Despite these headwinds, a contrarian bullish case is emerging. The company's Carelon Services segment is a key bright spot, with its contribution to operating gain growing from 6% in 2022 to 16% in the first half of 2025, largely fueled by the CareBridge acquisition. This growth is complemented by a significant insider purchase, with the CEO acquiring $2.4 million in shares, and a valuation that has compressed to multi-year lows. Long-term industry tailwinds, such as a projected 6-7% CAGR and an aging demographic, provide a supportive backdrop for the company's planned expansion into Texas and Florida. However, considerable risk remains from potential regulatory changes like the 'One Big Beautiful Bill Act,' which is estimated to reduce the insured population by 3.6% to 5.3%.

Key Decisions for Investors

• Investors could view the recent 20% stock price decline and resulting depressed valuation as a compelling entry point for a contrarian investment, especially given the strong signal from the CEO's recent insider purchase.
• It is critical to monitor the company's ability to control its medical loss ratio and the margin performance of its core Health Benefits segment in upcoming quarters, as this is the primary source of current earnings pressure.
• The growth trajectory and profitability of the Carelon Services segment should be tracked closely, as its increasing contribution to operating profit is the central pillar of the bull thesis and a key offset to weakness elsewhere.
• Investors should remain cautious of regulatory risk, particularly developments related to the 'One Big Beautiful Bill Act,' as legislative changes could materially impact industry-wide revenues and sentiment.